

## Versameb Upcoming 2021 Virtual Conference Calendar

**11 March 2021, Basel, Switzerland:** Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, announces that its management team will be presenting at / attending the following virtual conferences.

### [BioCapital Europe](#)

Thursday, 11 March 2021

### [WuXi Healthcare Forum 2021](#)

15-18 March 2021

Klaas Zuideveld, Chief Executive Officer & Isabel Ferreira, Chief Business Officer will be co-hosting the CEO Roundtable on 16 March at 15:30-16:00 CET

### [Bio-Europe Spring](#)

22-25 March 2021

### [BioEquity Europe](#)

17-19 May 2021

### [Anglonordic Life Science Conference](#)

25-26 May 2021

If you would like to meet with Versameb, please contact us at the details provided below. For more information, please visit us at <https://versameb.com/upcoming-conferences-events/>

#### **For further information:**

##### **Versameb**

Dr Klaas Zuideveld, CEO  
Hochbergerstrasse 60C  
4057 Basel, Switzerland  
[ir@versameb.com](mailto:ir@versameb.com)

##### **Optimum Strategic Communications**

Mary Clark, Eva Haas, Supriya Mathur  
Tel: +44 (0) 203 950 9144  
[versameb@optimumcomms.com](mailto:versameb@optimumcomms.com)

#### **NOTES TO EDITORS**

##### **About Versameb**

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb’s proprietary technology platform, *VERSagile*, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors with a focus on Renal Cell Carcinoma (RCC) and Head and Neck Cancer (H&N). Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at [www.versameb.com](http://www.versameb.com) as well as on [LinkedIn](#).